Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023 16:30 ET
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 30, 2023 16:30 ET
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023 19:41 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
ProLynx announces publication and initiation of patient recruitment for a trial of once-monthly treatment of diabetes in cats
September 05, 2019 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Today, ProLynx announced publication of data supporting therapy of Type 2 diabetes in cats with PLX039, a GLP-1 receptor agonist that can be...